BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Glenmark's consolidated revenues grow 2.8% to Rs 1,09,439 M in FY21

31 May 2021 | News

Registers consolidated net profit of Rs 9,701 M with growth of 25 per cent in FY21



Glenmark Pharmaceuticals announced its financial results for the fourth quarter and year ended March 31, 2021. For the fourth quarter of FY 2020-21, Glenmark's consolidated revenue was at Rs 28,599 million as against Rs 27,675 million recording an increase of 3.3 per cent.
Consolidated EBITDA grew by 12.4 per cent to Rs 5,234 million in the quarter ended March 31, 2021 as against Rs 4,657 million in the previous corresponding quarter.

The consolidated net profit was at Rs 2,339 million for the quarter ended March 31, 2021 as compared to Rs 2,203 million in the previous corresponding quarter, registering an increase of 6.2 per cent.

For the year ended March 31, 2021, Glenmark's consolidated revenue was at Rs 1,09,439 million as against Rs 1,06,410 million, recording an increase of 2.8 per cent over the previous corresponding period. The consolidated EBITDA for the fiscal year ended March 31, 2021 stood at Rs 20,844 million as against Rs 16,981 million, recording an increase of 22.7 per cent in the previous corresponding period. Consolidated net profit grew by 25 per cent to Rs 9,701 million for the year ended March 31, 2021, as against Rs 7,760 million in the previous year. Earnings Per Share (EPS) is at Rs 34.38 as compared to Rs 27.5 in the previous year.

"We delivered consistent performance during the year despite operational challenges due to the COVID-19 pandemic. We led from the front in India's fight against the pandemic at its very onset, with our leading brand FabiFlu," said Glenn Saldanha, CMD, Glenmark Pharmaceuticals. He further added, "We have in place strategic levers to grow our businesses sustainably, with a focus on strengthening our balance sheet."